Vincent Aurentz - 21 Feb 2025 Form 3/A - Amendment Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Director
Signature
/s/ Mark Iwicki, attorney-in-fact
Issuer symbol
IKT
Transactions as of
21 Feb 2025
Net transactions value
$0
Form type
3/A - Amendment
Filing time
28 Aug 2025, 19:50:18 UTC
Date Of Original Report
25 Feb 2025
Previous filing
02 Dec 2024
Next filing
02 Jul 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Aurentz Vincent Director 1000 N. WEST STREET, SUITE 1200, WILMINGTON /s/ Mark Iwicki, attorney-in-fact 28 Aug 2025 0001657494

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IKT Common Stock 765,895 21 Feb 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 3 amendment is being filed solely to include shares of common stock which were inadvertently omitted from the original Form 3 filed by the Reporting Person on February 25, 2025.
F2 Represents shares of common stock issued to the Reporting Person as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. ("CorHepta") on February 21, 2025 (the "Closing Date") by the Issuer, pursuant to the Agreement and Plan of Merger and Reorganization by and among the Issuer, Project IKT Merger Sub, Inc., CorHepta, and Preston S. Klassen, solely in his capacity as sellers' representative. Of these, 127,649 shares vested on the Closing Date, 382,947 shares shall vest on the first anniversary of the Closing Date. 25% of the remaining 255,299 shares will vest upon achievement of a certain milestone and 75% will vest on the first anniversary of the Closing Date, subject to the Reporting Person's continued service through such date; provided that, if the milestone is not achieved by the first anniversary of the Closing Date, all 255,299 shares shall be forfeited.